Realm Therapeutics - Presents at Wedbush PacGrow Healthcare Conference

August 8, 2018
RNS Number : 1132X
Realm Therapeutics PLC
08 August 2018

Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference



MALVERN, PA, August 8, 2018 - Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announces today that Alex Martin, CEO, will be presenting at the 2018 Wedbush PacGrow Healthcare Conference, on Tuesday, August 14, 2018 at 4:15 p.m. ET at the Parker New York.


A live and archived webcast of the Wedbush presentation will be available on the Events and Presentations page of the Company's website at


About Realm Therapeutics


Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signalling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris, and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit






Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US:  +44 (0) 20 3727 1000

US:  +1 212 600 1902


Argot Partners

Stephanie Marks / Claudia Styslinger

+1 212 600 1902


FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000


N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Search Investor Relations